Autopsy report · NCT01554085

First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

“ALS-2158 showed insufficient antiviral activity to warrant proceeding with further clinical development.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 9 months before it stopped.
• 78 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Alios Biopharma Inc.

Sponsor type

Industry

Conditions

Hepatitis C, Chronic

Interventions

ALS-002158; Placebo

Participants

78

Sites

5

Countries

Australia, New Zealand

Trials that died the same way

• TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin
  “Antiviral activity was considered insufficient to warrant further clinical development of TMC649128.” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.